The scientist’s investigation covers issues in Internal medicine, Fatty liver, Gastroenterology, Pathology and Fibrosis. He has included themes like Endocrinology and Surgery in his Internal medicine study. His Fatty liver research integrates issues from Steatosis, Surgical oncology, Liver injury and Chemotherapy.
His research in Gastroenterology intersects with topics in Severity of illness, Metabolic syndrome and Hepatitis. His work carried out in the field of Pathology brings together such families of science as Epithelial–mesenchymal transition and Alcoholic liver disease. Alastair D. Burt interconnects Chronic liver disease and Cirrhosis in the investigation of issues within Fibrosis.
Alastair D. Burt spends much of his time researching Internal medicine, Pathology, Gastroenterology, Fatty liver and Fibrosis. His work on Liver biopsy, Biopsy and Cirrhosis as part of general Internal medicine study is frequently linked to In patient, bridging the gap between disciplines. His study in Liver biopsy is interdisciplinary in nature, drawing from both Liver transplantation and Surgery.
His Pathology research is multidisciplinary, incorporating elements of Hepatocellular carcinoma, Liver injury and Alcoholic liver disease. His Gastroenterology study frequently draws connections to other fields, such as Nonalcoholic fatty liver disease. Much of his study explores Fatty liver relationship to Steatosis.
His primary areas of study are Internal medicine, Fatty liver, Pathology, Gastroenterology and Steatohepatitis. His work on Fibrosis, Colonoscopy and Biopsy as part of general Internal medicine study is frequently connected to In patient, therefore bridging the gap between diverse disciplines of science and establishing a new relationship between them. His work focuses on many connections between Fatty liver and other disciplines, such as Steatosis, that overlap with his field of interest in Mitochondrion, Hepatocyte and Proinflammatory cytokine.
His research on Pathology focuses in particular on Histopathology. His Gastroenterology study combines topics in areas such as Body mass index, Randomized controlled trial, Non invasive, Nonalcoholic fatty liver disease and Non alcoholic. His research on Steatohepatitis also deals with topics like
His primary areas of investigation include Fatty liver, Internal medicine, Gastroenterology, Steatosis and Pathology. Alastair D. Burt mostly deals with Steatohepatitis in his studies of Fatty liver. In general Internal medicine study, his work on Fibrosis, Colorectal cancer, Colonoscopy and Randomized controlled trial often relates to the realm of Aspartate Aminotransferases, thereby connecting several areas of interest.
His Gastroenterology research includes elements of Liver pathology, Predictive value of tests, Non invasive and Hyperplastic Polyp. As a part of the same scientific family, Alastair D. Burt mostly works in the field of Steatosis, focusing on Cirrhosis and, on occasion, Liver biopsy and Nonalcoholic fatty liver disease. His work on Biopsy and Carcinoma as part of general Pathology research is frequently linked to Sign out and Columnar Metaplasia, bridging the gap between disciplines.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD
Paul Angulo;Jason M. Hui;Giulio Marchesini;Ellisabetta Bugianesi.
Serum markers detect the presence of liver fibrosis: A cohort study
William M.C. Rosenberg;Michael Voelker;Robert Thiel;Michael Becka.
The natural history of nonalcoholic fatty liver: A follow-up study
Mohd R. Teli;Oliver F. W. James;Alastair D. Burt;Mark K. Bennett.
Pathologic Diagnosis of Early Hepatocellular Carcinoma: A Report of the International Consensus Group for Hepatocellular Neoplasia
Masamichi Kojiro;Ian R. Wanless;Venancio Alves;Sunil Badve.
Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management
Stuart McPherson;Stuart McPherson;Tim Hardy;Elsbeth Henderson;Alastair D. Burt;Alastair D. Burt.
Journal of Hepatology (2015)
Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers.
Indra Neil Guha;Julie Parkes;Paul Roderick;Dipanker Chattopadhyay.
Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease
Stuart McPherson;Stephen F Stewart;Elsbeth Henderson;Alastair D Burt.
EASL Clinical Practical Guidelines: Management of Alcoholic Liver Disease
Philippe Mathurin;Antoine Hadengue;Giovanni Addolorato;Alastair Burt.
Journal of Hepatology (2012)
Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver.
M.R Teli;C.P Day;O.F.W James;A.D Burt.
The Lancet (1995)
TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease
Yang-Lin Liu;Helen L Reeves;Alastair D Burt;Dina Tiniakos.
Nature Communications (2014)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: